Information for investor
Innovative drug development projects
1. Antithrombotic drug Granik® (GRS) for the prevention of thrombotic complications and treatment of cardiovascular diseases. GRS is a new generation antithrombotic drug combining antithrombotic and antihypertensive effects and the ability to eliminate endothelial dysfunction - the underlying cause of cardiovascular pathology. Patented in Russia, USA, EU, additional patenting is underway. Market segment (B01A): global - over $40 billion, Russian - over 70 billion RUB. A Phase II clinical trial of GRS in patients with IHD (stable angina I-III FC) after endovascular revascularization was successfully completed; preparations for a Phase III clinical trial are underway; transfer of substance and drug production technology to the production facility of the Russian investor (JSC “Organica”) is underway.
2. Drug for treating Parkinson’s disease Prottremin® (DIOL) – first-in-class drug that allows to use a new therapeutic strategy based on neuroprotection and neuroregeneration rather than dopamine deficiency replacement. Patented in Russia, USA, EU. Market segment (N04): global - over $6 billion, Russian - over 4 billion RUB. Phase Ia and Ib clinical trials (in healthy subjects) have been completed; the Russian Ministry of Health has authorized Phase IIa clinical trials (on patients with drug-induced Parkinsonism); preparations are underway for Phase II clinical trials in patients with Parkinson's disease.
3. Analgesic drug PAV – first-in-class non-narcotic analgesic, which combines potency and safety in long-term use, which is unattainable for existing analgesics. Patented in Russia, EAEU, USA, EU, China, India, Japan. Market segment (N02): global - over $50 billion, Russian - over 35 billion RUB. Phase Ia and Ib clinical trials in healthy subjects will be completed in November 2023; transfer of substance and drug production technology to the production facility of the Russian investor (JSC “Organica”) is underway.
4. Antiviral drug for influenza treatment Camphecin® – the first inhibitor of specific viral protein hemagglutinin in the market. Effective against a wide range of influenza viruses, including epidemically relevant subtypes (at the level of the treatment standard - Tamiflu). Patented in Russia. Market segment: Russian - over 50 billion RUB. Preclinical studies have been completed; permission for Phase I clinical trials has been granted by the Russian Ministry of Health.
5. Anti-inflammatory drug IML – a unique NSAID with high efficacy and safety in long-term threatment with antiviral properties. Promising for use in various dosage forms (capsules, injectable forms, ointments). Patented in Russia, foreign patenting is being prepared. Market segment (M01A): global - over $10 billion, Russian - over 45 billion RUB. Preclinical studies are being finalized.
6. Anti-inflammatory drug LIS – first-in-class inhibitor of inducible NO synthase - an innovative solution for the treatment of inflammatory (ulcerative colitis, Crohn's disease) and other intestinal diseases. Patented in Russia, EAEU, USA, EU. Market segment: global - over $10 billion, Russian - over 15 billion RUB. Preclinical studies are ongoing.
7. Analgesic drug CHR – first-in-class analgesic - agonist of cannabinoid CB1 receptors and dopamine D1- and D3-receptors. Promising for the treatment of chronic pain syndrome in cancer patients, neuropathic pain syndrome. Patented in Russia, EAEU, USA, EU, China. Market segment (N02): global - overn $50 billion, Russian - over 35 billion RUB. Preclinical studies are ongoing.
8. Biotechnological product PlantAP – an innovative product based on plant cells containing human intestinal alkaline phosphatase for the prevention of systemic diseases associated with intestinal barrier disorders. Patented in Russia, patenting is underway in the EAEU, USA, EU, China. Market segment: global - over $40 billion, Russian - over 30 billion RUB. Efficacy has been studied in pathology models; production technology is being tested and scaled up.
We invite pharmaceutical companies interested in expanding the product line with innovative drugs to partner with us.
We invite investors to complete projects and prepare them for sale to domestic and foreign pharmaceutical companies.